OM-85 in the prevention/treatment of respiratory infections and exacerbations of chronic lung diseases: selection criteria, mechanisms and evidence
Abstract
The review presents the criteria for a new classification of immunomodulatory drugs, which can be useful for a general practitioner. These criteria facilitate the selection of immunostimulant/immunomodulator in a specific clinical situation. Through the prism of these criteria, this paper provides information on the mechanisms and evidence of the prophylactic and, separately, therapeutic effectiveness of bacterial lysates, in particular OM-85 as one of the most studied and tested immunomodulators.
References
1. Хаитов Р. М., Пинегин Б. В. Иммуномодуляторы и некоторые аспекты их клинического применения // Клиническая медицина. 1996. Т. 74. № 8. С. 7–12.
2. Караулов А. В., Калюжин О. В. Иммунотропные препараты: принципы применения и клиническая эффективность. М.: МЦФЭР, 2007.
3. Сепиашвили Р. И. Иммунотропные препараты: классификация, проблемы и перспективы // Аллергология и иммунология. 2015. Т. 16. № 1. С. 64–69.
4. Хаитов Р. М., Пинегин Б. В. Современные иммуномодуляторы. Классификация. Механизм действия. М.: Фармарус Принт, 2005.
5. Калюжин О. В. Безопасность и физиологичность действия пробиотиков как средств иммунокоррекции // Российский аллергологический журнал. 2013. № 3. С. 45–56.
6. Del-Rio-Navarro B. E., Espinosa Rosales F., Flenady V., Sienra-Monge J. J. L. Immunostimulants for preventing respiratory tract infection in children // Cochrane Database of Systematic Reviews. 2006; (2): CD004974. DOI: 10.1002/14651858.CD004974.pub2.
7. Barr S. E., Brown H., Fuchs M. et al. A double-blind study of the effects of bacterial vaccine on infective asthma // Journal of Allergy and Clinical Immunology. 1965; 36: 47–61.
8. Fontana V. J., Salanitro A. S., Wolfe H. I., Moreno F. Hyposensitization with bacterial vaccine in infectious asthma. A double-blind study and a longitudinal study // JAMA. 1965; 193: 895–900.
9. Mueller H. L., Lanz M. Hyposensitization with bacterial vaccine in infectious asthma. A double-blind study and a longitudinal study // JAMA. 1969; 208: 1379–1383.
10. Rytel M. W., Ferstenfeld J. E., Rose H. D. et al. Efficacy of a «mixed bacterial vaccine» in prophylaxis of acute respiratory infections: possible role of interferon // American Journal of Epidemiology. 1974; 99: 347–359.
11. Lachard J., Jars G., Fourestier J. Clinical study of a new drug: Imudon, in the treatment of diseases of the oral mucosa and periodontium // Sem. Hop. Ther. 1975. Vol. 51 (3). P. 177–182 (French).
12. Калюжин О. В. Новый бактериальный лизат в терапии рецидивирующих респираторных инфекций: взгляд иммунолога // Русский медицинский журнал. 2015. № S. С. 2–4.
13. Калюжин О. В. Топические бактериальные лизаты в профилактике и лечении респираторных инфекций // Практическая медицина. 2016. № 2–2 (94). С. 69–74.
14. De Benedetto F., Sevieri G. Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art // Multidisciplinary Respiratory Medicine. 2013; 8 (1): Art. 33. DOI: 10.1186/2049–6958–8-33.
15. Mabbott N. A., Donaldson D. S., Ohno H., Williams I. R., Mahajan A. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium // Mucosal immunology. 2013; 6: 666–677. DOI: 10.1038/mi.2013.30.
16. Калюжин О. В. Феномен тренированного иммунитета и механизмы действия неспецифических иммуномодуляторов // Российский аллергологический журнал. 2015. № 4. С. 45–51.
17. Nizet V. Bacteria and phagocytes: mortal enemies // J. Innate Immun. 2010; 2 (6): 505–507. DOI: 10.1159/000320473.
18. Hertzеn E., Johansson L., Wallin R. et al. M1-protein dependent intracellular trafficking promotes persistence and replication of Streptococcus pyogenes in macrophages // J. Innate Immun. 2010; 2: 534–545.
19. Van Avondt K., van Sorge N. M., Meyaard L. Bacterial Immune Evasion through Manipulation of Host Inhibitory Immune Signaling // PLoS Pathogens. 2015; 11 (3): e1004644. DOI: 10.1371/journal.ppat.1004644.
20. Valle J., Latasa C., Gil C. et al. Bap, a Biofilm Matrix Protein of Staphylococcus aureus Prevents Cellular Internalization through Binding to GP96 Host Receptor // PLoS Pathogens. 2012; 8 (8): e1002843. DOI: 10.1371/journal.ppat.1002843.
21. Parola C., Salogni L., Vaira X. et al. Selective Activation of Human Dendritic Cells by OM-85 through a NF-kB and MAPK Dependent Pathway // PLoS ONE. 2013; 8 (12): e82867. DOI: 10.1371/journal.pone.0082867.
22. Zelle-Rieser C., Ramoner R., Bartsch G., Thurnher M. A clinically approved oral vaccine against pneumotropic bacteria induces the terminal maturation of CD83+ immunostimulatory dendritic cells // Immunol. Lett. 2001; 76 (1): 63–67.
23. Dang A. T., Pasquali C., Ludigs K., Guarda G. OM-85 is an immunomodulator of interferon-? production and inflammasome activity // Scientific Reports. 2017; 7: 43844. DOI: 10.1038/srep43844.
24. Huber M., Mossmann H., Bessler W. G. Th1-orientated immunological properties of the bacterial extract OM-85-BV // Eur. J. Med. Res. 2005; 10 (5): 209–217.
25. Pasquali C., Salami O., Taneja M. et al. Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract // Frontiers in Medicine. 2014; 1: 41. DOI: 10.3389/fmed.2014.00041.
26. Roth M., Pasquali C., Stolz D., Tamm M. Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP // PLoS ONE. 2017; 12 (11): e0188010. DOI: 10.1371/journal.pone.0188010.
27. Steurer-Stey C., Bachmann L. M., Steurer J., Tram?r M. R. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review // Chest. 2004; 126: 1645–1655. DOI: 10.1378/chest.126.5.1645.
28. Sprenkle M. D., Niewoehner D. E., MacDonald R., Rutks I., Wilt T. J. Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review // COPD. 2005; 2 (1): 167–175.
29. Schaad U. B. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review // World J. Pediatr. 2010; 6: 5–12. DOI: 10.1007/s12519–010–0001-x.
30. Del-Rio-Navarro B. E., Espinosa-Rosales F. J., Flenady V., Sienra-Mongen J. J. L. Immunostimulants for preventing respiratory tract infection in children // Evid. Based Child Health. 2012; 7: 629–717. DOI: 10.1002/ebch.1833.
31. Yin J., Xu B., Zeng X., Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis // Int. Immunopharmacol. 2018 Jan; 54: 198–209. DOI: 10.1016/j.intimp.2017.10.032.
32. G?mez Barreto D., De la Torre C., Alvarez A., Faure A., Berber A. Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children // Allergol. Immunopathol. (Madr). 1998; 26 (1): 17–22. [Article in Spanish].
33. Heintz B., Schlenter W. W., Kirsten R., Nelson K. Clinical efficacy of Broncho-Vaxom in adult patients with chronic purulent sinusitis — a multi-centric, placebo-controlled, double-blind study // Int. J. Clin. Pharmacol. Ther. Toxicol. 1989; 27 (11): 530–534.
34. Zagar S., L?fler-Badzek D. Broncho-Vaxom in children with rhinosinusitis: a double-blind clinical trial // ORL J. Otorhinolaryngol. Relat. Spec. 1988; 50 (6): 397–404.
35. Liu Y. W., Dong S. H., Zhan G. Y., Tan H. Z., Peng Y. Q., Wei F. Analysis of the effect of bacterial lysate and the immunologic mechanism in treating infant bronchiolitis // Eur. Rev. Med. Pharmacol. Sci. 2017; 21 (14): 3332–3336.
Review
For citations:
Kalyuzhin O.V. OM-85 in the prevention/treatment of respiratory infections and exacerbations of chronic lung diseases: selection criteria, mechanisms and evidence. Lechaschi Vrach. 2018;(3):77. (In Russ.)
Views:
638
JATS XML
Email this article 
